SNC
REGN icon

Stifel Nicolaus & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Stifel Nicolaus & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$433K Buy
1,384
+144
+12% +$37.9K 0.01% 965
2013
Q2 		$279K Buy
+1,240
New +$289K 0.01% 1118

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stifel Nicolaus & Co's REGN Position: Q3 2013 in Review

Stifel Nicolaus & Co increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q3 2013, buying an estimated $37.9K and bringing the position to 1,384 shares worth $433K. The position accounts for 0.01% of the portfolio, ranked #965.

Stifel Nicolaus & Co first reported a position in REGN in Q2 2013 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold REGN as of Q3 2013.

  • Stifel Nicolaus & Co held 1,384 shares of Regeneron Pharmaceuticals worth $433K as of Q3 2013.
  • Stifel Nicolaus & Co bought 144 Regeneron Pharmaceuticals shares in Q3 2013, an estimated $37.9K.
  • Regeneron Pharmaceuticals made up 0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #965 holding.
  • Stifel Nicolaus & Co first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 2 quarters since.
  • 414 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.